Publicado 4 números por año
ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448
Indexed in
Aberrant B-Raf Signaling in Human Cancer − 10 Years from Bench to Bedside
SINOPSIS
The Ras/Raf/MEK/ERK signaling pathway plays a key role in physiological processes and is often dysregulated in cancer as well as developmental disorders such as the neuro-cardio-facio-cutaneous syndromes. Raf proteins, and in particular B-Raf, represent an important regulatory node, which is reflected by the fact that B-Raf represents the most frequently mutated protein kinase gene in human tumors. Many genetic aberrations of the BRAF proto-oncogene, such as different point mutations and chromosomal rearrangements, have been reported since 2002. As B-Raf displays aberrant activity in tumor entities for which no or only limited effective therapies are available, e.g., melanoma, ovarian, and colorectal carcinoma, a lot of hope and effort has been placed on strategies inhibiting its activity. Indeed, recent clinical trials involving B-Raf selective inhibitors exhibited unprecedented response rates in metastatic melanoma patients. However, this therapeutic response is short-lived due to the emergence of several resistance mechanisms. Here we provide a review of our current knowledge on the regulation of this kinase under physiological circumstances and how this control is lost by mutations. We give an update on malignancies displaying high frequencies of BRAF mutations and discuss the mechanisms underlying the side effects and drug resistance phenomena associated with Raf inhibitors.
-
Pakladok Tatsiana, Hosseinzadeh Zohreh, Alesutan Ioana, Lang Florian, Stimulation of the Na+-coupled glucose transporter SGLT1 by B-RAF, Biochemical and Biophysical Research Communications, 427, 4, 2012. Crossref
-
Aravalli Rajagopal N., Cressman Erik N. K., Steer Clifford J., Cellular and molecular mechanisms of hepatocellular carcinoma: an update, Archives of Toxicology, 87, 2, 2013. Crossref
-
González Mercedes, Cerecetto Hugo, Quinoxaline derivatives: a patent review (2006 – present), Expert Opinion on Therapeutic Patents, 22, 11, 2012. Crossref
-
Machesky Laura M., Sansom Owen J., Rac1 in the driver’s seat for melanoma, Pigment Cell & Melanoma Research, 25, 6, 2012. Crossref
-
Freeman Alyson K, Ritt Daniel A, Morrison Deborah K, The importance of Raf dimerization in cell signaling, Small GTPases, 4, 3, 2013. Crossref
-
Yaktapour Niuscha, Übelhart Rudolf, Schüler Julia, Aumann Konrad, Dierks Christine, Burger Meike, Pfeifer Dietmar, Jumaa Hassan, Veelken Hendrik, Brummer Tilman, Zirlik Katja, Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia, Blood, 122, 9, 2013. Crossref
-
Baljuls Angela, Kholodenko Boris N., Kolch Walter, It takes two to tango – signalling by dimeric Raf kinases, Mol. BioSyst., 9, 4, 2013. Crossref
-
Field Jeffrey, Manser Ed, The PAKs come of age, Cellular Logistics, 2, 2, 2012. Crossref
-
Uhara Hisashi, Ashida Atsuko, Koga Hiroshi, Ogawa Eisaku, Uchiyama Aya, Uchiyama Ryuhei, Hayashi Koichi, Kiniwa Yukiko, Okuyama Ryuhei, NRAS mutations in primary and metastatic melanomas of Japanese patients, International Journal of Clinical Oncology, 19, 3, 2014. Crossref
-
Xie Tian, Peng Wei, Liu Yexing, Yan Chuangye, Maki Jenny, Degterev Alexei, Yuan Junying, Shi Yigong, Structural Basis of RIP1 Inhibition by Necrostatins, Structure, 21, 3, 2013. Crossref
-
Khazak Vladimir, Eyrisch Susanne, Kato Juran, Tamanoi Fuyuhiko, Golemis Erica A., A Two-Hybrid Approach to Identify Inhibitors of the RAS–RAF Interaction, in Inhibitors of the Ras Superfamily G-proteins, Part A, 33, 2013. Crossref
-
Pakladok Tatsiana, Hosseinzadeh Zohreh, Lebedeva Aleksandra, Alesutan Ioana, Lang Florian, Upregulation of the Na+-Coupled Phosphate Cotransporters NaPi-IIa and NaPi-IIb by B-RAF, The Journal of Membrane Biology, 247, 2, 2014. Crossref
-
Ascierto Paolo A, Schadendorf Dirk, Berking Carola, Agarwala Sanjiv S, van Herpen Carla ML, Queirolo Paola, Blank Christian U, Hauschild Axel, Beck J Thaddeus, St-Pierre Annie, Niazi Faiz, Wandel Simon, Peters Malte, Zubel Angela, Dummer Reinhard, MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study, The Lancet Oncology, 14, 3, 2013. Crossref
-
McKelvie Penelope A., Chan Fiona, Yu Yong, Waring Paul, Gresshoff Irma, Farrell Stephen, Williams Richard A., The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry, Pathology, 45, 7, 2013. Crossref
-
Fuchs Serge Y., Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy, Journal of Interferon & Cytokine Research, 33, 4, 2013. Crossref
-
Hemminger J.A., Lozanski G., Molecular Pathology of Chronic Lymphocytic Leukemia and Relevance to Novel Therapies, in Pathobiology of Human Disease, 2014. Crossref
-
Coupe Nicholas, Corrie Pippa, Hategan Mirela, Larkin James, Gore Martin, Gupta Avinash, Wise Adelyn, Suter Sam, Ciria Cristian, Love Sharon, Collins Linda, Middleton Mark R., PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel, European Journal of Cancer, 51, 3, 2015. Crossref
-
Yaktapour Niuscha, Meiss Frank, Mastroianni Justin, Zenz Thorsten, Andrlova Hana, Mathew Nimitha R., Claus Rainer, Hutter Barbara, Fröhling Stefan, Brors Benedikt, Pfeifer Dietmar, Pantic Milena, Bartsch Ingrid, Spehl Timo S., Meyer Philipp T., Duyster Justus, Zirlik Katja, Brummer Tilman, Zeiser Robert, BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemia, Journal of Clinical Investigation, 124, 11, 2014. Crossref
-
Dudley Jonathan C., Gurda Grzegorz T., Tseng Li-Hui, Anderson Derek A., Chen Guoli, Taube Janis M., Gocke Christopher D., Eshleman James R., Lin Ming-Tseh, Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in Melanoma, Molecular Diagnosis & Therapy, 18, 4, 2014. Crossref
-
Grimaldi Antonio M., Simeone Ester, Ascierto Paolo A., The role of MEK inhibitors in the treatment of metastatic melanoma, Current Opinion in Oncology, 26, 2, 2014. Crossref
-
Lloyd K. C. Kent, Khanna Chand, Hendricks William, Trent Jeffrey, Kotlikoff Michael, Precision medicine: an opportunity for a paradigm shift in veterinary medicine, Journal of the American Veterinary Medical Association, 248, 1, 2016. Crossref
-
Hou Jiayun, Zhang Yong, Zhu Zhitu, Gene heterogeneity in metastasis of colorectal cancer to the lung, Seminars in Cell & Developmental Biology, 64, 2017. Crossref
-
Egeler R. Maarten, Katewa Satyendra, Leenen Pieter J.M., Beverley Peter, Collin Matthew, Ginhoux Florent, Arceci Robert J., Rollins Barrett J., Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci, Pediatric Blood & Cancer, 63, 10, 2016. Crossref
-
Pakladok Tatsiana, Hosseinzadeh Zohreh, Almilaji Ahmad, Lebedeva Aleksandra, Shumilina Ekaterina, Alesutan Ioana, Lang Florian, Barnes Steven, Up-Regulation of hERG K+ Channels by B-RAF, PLoS ONE, 9, 1, 2014. Crossref
-
Brummer Tilman, BRaf-Signaling, in Encyclopedia of Cancer, 2017. Crossref
-
Brummer Tilman, BRAF Somatic Alterations, in Encyclopedia of Cancer, 2017. Crossref
-
Grimaldi Antonio M., Simeone Ester, Festino Lucia, Vanella Vito, Strudel Martina, Ascierto Paolo A., MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors, American Journal of Clinical Dermatology, 18, 6, 2017. Crossref
-
Geng Jiangqiao, Wang Huanmin, Liu Yuanhu, Tai Jun, Jin Yaqiong, Zhang Jie, He Lejian, Fu Libing, Qin Hong, Song Yingluan, Su Jinzhu, Zhang Aiying, Wen Xin, Guo Yongli, Ni Xin, Correlation between BRAF V600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma, Science China Life Sciences, 60, 7, 2017. Crossref
-
WEI RUI, WANG ZHONGQING, LI XIAOLIN, SHU YIGANG, FU BIN, Frequent BRAFV600E mutation has no effect on tumor invasiveness in patients with Langerhans cell histiocytosis, Biomedical Reports, 1, 3, 2013. Crossref
-
LI BIN, LU JING CHEN, HE DAN, WANG JUN, ZHOU HUI, SHEN LIANGFANG, ZHANG CHUNFANG, DUAN CHAOJUN, Rapid onset lung squamous cell carcinoma with prominent peritoneal carcinomatosis and an eosinophilic leukemoid reaction, with coexistence of the BRAF V600E and oncogenic KRAS G12A mutations: A case report, Oncology Letters, 8, 2, 2014. Crossref
-
Neal Donald E, Derwae Amanda L, Etzkorn Jeremy R, Cells to Surgery Quiz: March 2018, Journal of Investigative Dermatology, 138, 3, 2018. Crossref
-
Brummer Tilman, B-Raf Somatic Alterations, in Encyclopedia of Cancer, 2014. Crossref
-
Brummer Tilman, B-Raf Signaling, in Encyclopedia of Cancer, 2014. Crossref
-
Köhler Martin, Ehrenfeld Sophia, Halbach Sebastian, Lauinger Manuel, Burk Ulrike, Reischmann Nadine, Cheng Shuofei, Spohr Corinna, Uhl Franziska Maria, Köhler Natalie, Ringwald Kathrin, Braun Sandra, Peters Christoph, Zeiser Robert, Reinheckel Thomas, Brummer Tilman, B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model, Oncogene, 38, 8, 2019. Crossref
-
Freeman Alyson K., Morrison Deborah K., Mechanisms and Potential Therapies for Acquired Resistance to Inhibitors Targeting the Raf or MEK Kinases in Cancer, in Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy, 1, 2013. Crossref
-
Aravalli Rajagopal N., Steer Clifford J., Molecular Mechanisms of HCC, in Hepatocellular Carcinoma, 2014. Crossref
-
Köhler Martin, Röring Michael, Schorch Björn, Heilmann Katharina, Stickel Natalie, Fiala Gina J, Schmitt Lisa C, Braun Sandra, Ehrenfeld Sophia, Uhl Franziska M, Kaltenbacher Thorsten, Weinberg Florian, Herzog Sebastian, Zeiser Robert, Schamel Wolfgang W, Jumaa Hassan, Brummer Tilman, Activation loop phosphorylation regulates B‐Raf in vivo and transformation by B‐Raf mutants , The EMBO Journal, 35, 2, 2016. Crossref
-
Diedrich Britta, Rigbolt Kristoffer TG, Röring Michael, Herr Ricarda, Kaeser‐Pebernard Stephanie, Gretzmeier Christine, Murphy Robert F, Brummer Tilman, Dengjel Jörn, Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition , The EMBO Journal, 36, 5, 2017. Crossref
-
Parsyan Armen, Sullivan Ryan J., Meguerditchian Ari-Nareg, Meterissian Sarkis, Melanoma and Non-Melanoma Skin Cancers, in Translation and Its Regulation in Cancer Biology and Medicine, 2014. Crossref
-
Morkel Markus, Riemer Pamela, Bläker Hendrik, Sers Christine, Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance, Oncotarget, 6, 25, 2015. Crossref
-
Eisenhardt Anja E., Sprenger Adrian, Röring Michael, Herr Ricarda, Weinberg Florian, Köhler Martin, Braun Sandra, Orth Joachim, Diedrich Britta, Lanner Ulrike, Tscherwinski Natalja, Schuster Simon, Dumaz Nicolas, Schmidt Enrico, Baumeister Ralf, Schlosser Andreas, Dengjel Jörn, Brummer Tilman, Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles, Oncotarget, 7, 18, 2016. Crossref
-
Behar Marcelo, Barken Derren, Werner Shannon L., Hoffmann Alexander, The Dynamics of Signaling as a Pharmacological Target, Cell, 155, 2, 2013. Crossref
-
Catalano Antonella, Adlesic Mojca, Kaltenbacher Thorsten, Klar Rhena F. U., Albers Joachim, Seidel Philipp, Brandt Laura P., Hejhal Tomas, Busenhart Philipp, Röhner Niklas, Zodel Kyra, Fritsch Kornelia, Wild Peter J., Duyster Justus, Fritsch Ralph, Brummer Tilman, Frew Ian J., Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition, Cancers, 13, 8, 2021. Crossref
-
Schenone Silvia, Radi Marco, Musumeci Francesca, Brullo Chiara, Botta Maurizio, Biologically Driven Synthesis of Pyrazolo[3,4-d]pyrimidines As Protein Kinase Inhibitors: An Old Scaffold As a New Tool for Medicinal Chemistry and Chemical Biology Studies, Chemical Reviews, 114, 14, 2014. Crossref
-
Freeman Alyson K., Ritt Daniel A., Morrison Deborah K., Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling, Molecular Cell, 49, 4, 2013. Crossref
-
Rezaei Adariani Soheila, Buchholzer Marcel, Akbarzadeh Mohammad, Nakhaei-Rad Saeideh, Dvorsky Radovan, Ahmadian Mohammad Reza, Structural snapshots of RAF kinase interactions, Biochemical Society Transactions, 46, 6, 2018. Crossref
-
Harlid Sophia, Van Guelpen Bethany, Qu Conghui, Gylling Björn, Aglago Elom K., Amitay Efrat L., Brenner Hermann, Buchanan Daniel D., Campbell Peter T., Cao Yin, Chan Andrew T., Chang‐Claude Jenny, Drew David A., Figueiredo Jane C., French Amy J., Gallinger Steven, Giannakis Marios, Giles Graham G., Gunter Marc J., Hoffmeister Michael, Hsu Li, Jenkins Mark A., Lin Yi, Moreno Victor, Murphy Neil, Newcomb Polly A., Newton Christina C., Nowak Jonathan A., Obón‐Santacana Mireia, Ogino Shuji, Potter John D., Song Mingyang, Steinfelder Robert S., Sun Wei, Thibodeau Stephen N., Toland Amanda E., Ugai Tomotaka, Um Caroline Y., Woods Michael O., Phipps Amanda I., Harrison Tabitha, Peters Ulrike, Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases, International Journal of Cancer, 151, 3, 2022. Crossref
-
McCarthy Jeanette J., McLeod Howard L., Ginsburg Geoffrey S., Genomic Medicine: A Decade of Successes, Challenges, and Opportunities, Science Translational Medicine, 5, 189, 2013. Crossref
-
Favre Gilles, Le devenir des thérapeutiques ciblant la voie RAS/RAF/ MEK/ERK en cancérologie : l’exemple des mélanomes, Bulletin de l'Académie Nationale de Médecine, 198, 2, 2014. Crossref
-
Mitra Shahana, Ghosh Baijayanti, Gayen Nilanjan, Roy Joydeep, Mandal Atin K., Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation, Journal of Biological Chemistry, 291, 47, 2016. Crossref
-
Clerk Angela, Meijles Daniel N., Hardyman Michelle A., Fuller Stephen J., Chothani Sonia P., Cull Joshua J., Cooper Susanna T.E., Alharbi Hajed O., Vanezis Konstantinos, Felkin Leanne E., Markou Thomais, Leonard Samuel J., Shaw Spencer W., Rackham Owen J.L., Cook Stuart A., Glennon Peter E., Sheppard Mary N., Sembrat John C., Rojas Mauricio, McTiernan Charles F., Barton Paul J., Sugden Peter H., Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo , Biochemical Journal, 479, 3, 2022. Crossref
-
Krejci Pavel, The paradox of FGFR3 signaling in skeletal dysplasia: Why chondrocytes growth arrest while other cells over proliferate, Mutation Research/Reviews in Mutation Research, 759, 2014. Crossref